# Alexion Pharmaceuticals

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/alexion-pharmaceuticals/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | American company |
| OpenAlex ID | https://openalex.org/F4320309052 |
| ROR ID | https://ror.org/031ywxc85 |
| Works | 4,545 |

## Funder papers

- [Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/executive-summary-of-the-kdigo-2021-guideline-for-the-management-of-glomerular/)
- [<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes](https://scholariq.org/papers/i-egfr-i-mutant-adenocarcinomas-that-transform-to-small-cell-lung-cancer-and/)
- [KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary](https://scholariq.org/papers/kdigo-2025-clinical-practice-guideline-for-the-evaluation-management-and/)
- [Complement dysregulation in glomerulonephritis](https://scholariq.org/papers/complement-dysregulation-in-glomerulonephritis/)
- [Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA–Associated Vasculitis](https://scholariq.org/papers/executive-summary-of-the-kdigo-2024-clinical-practice-guideline-for-the-2/)
- [Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial](https://scholariq.org/papers/long-term-efficacy-and-safety-of-eculizumab-in-japanese-patients-with-pnh-aegis/)
- [Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial](https://scholariq.org/papers/spironolactone-versus-placebo-in-patients-undergoing-maintenance-dialysis/)
- [Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria](https://scholariq.org/papers/hemolysis-induced-by-sars-cov-2-mrna-vaccination-in-patients-with-paroxysmal/)
- [Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort](https://scholariq.org/papers/description-and-cross-sectional-analyses-of-25-880-adults-and-children-in-the-uk/)
- [Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients](https://scholariq.org/papers/results-from-multinational-phase-3-studies-of-ravulizumab-alxn1210-versus/)
- [Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF](https://scholariq.org/papers/sacubitril-valsartan-and-quality-of-life-assessed-using-the-euroqol-five/)
- [Health Care Resource Utilization and Productivity Impairment in Adults with Immunoglobulin A Nephropathy: A Real-World, Observational, Global Analysis](https://scholariq.org/papers/health-care-resource-utilization-and-productivity-impairment-in-adults-with/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.